US EditionPublished • loading... • Updated
ADMA Biologics Inc (ADMA) Stock Analysis: Uncovering Nearly 88% Growth Potential Amid Robust Analyst Ratings
Summary by DirectorsTalk Interviews
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
ADMA Biologics Inc (ADMA) Stock Analysis: Uncovering Nearly 88% Growth Potential Amid Robust Analyst Ratings
ADMA Biologics Inc (NASDAQ: ADMA), a prominent player in the biotechnology industry, is capturing significant attention with its substantial growth potential. With a market capitalization of $3.46 billion, ADMA is well-positioned in the healthcare sector, particularly in developing and marketing plasma-derived biologics. ADMA’s current stock price of $14.52, a modest 0.03% increase, is just a small increment within the 52-week range of $13.99 to…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
